Tenofovir-disoproxil-fumarate modulates lipid metabolism via hepatic CD36/PPAR-alpha activation in hepatitis B virus infection.

Kazuharu SuzukiGoki SudaYoshiya YamamotoKen FuruyaMasaru BabaAkinobu NakamuraHideaki MiyoshiMegumi KimuraOsamu MaeharaRen YamadaTakashi KitagatayaKoji YamamotoTaku ShigesawaAkihisa NakamuraMasatsugu OharaNaoki KawagishiMasato NakaiTakuya ShoMitsuteru NatsuizakaKenichi MorikawaKoji OgawaShunsuke OhnishiNaoya Sakamotonull null

Published in: Journal of gastroenterology (2020)

Tenofovir-disoproxil-fumarate modulates lipid metabolism by upregulating hepatic CD36 via PPAR-α activation. Since dyslipidemia could be associated with arteriosclerosis and hepatocarcinogenesis, these discoveries provide novel insights into anti-HBV therapies, as well as the associated extrahepatic effects of NA.

Keyphrases

fatty acid
hepatitis b virus
insulin resistance
antiretroviral therapy
nk cells
type diabetes
metabolic syndrome
liver failure